Select a medication above to begin.
Portrazza
necitumumab
Black Box Warnings .
Cardiopulmonary Arrest
3% incidence of cardiopulmonary arrest and/or sudden death in patients receiving necitumumab w/ cisplatin and gemcitabine; monitor electrolytes incl. Ca, Mg during/after tx
Hypomagnesemia
83% incidence in patients receiving necitumumab w/ cisplatin and gemcitabine, and was severe in 20% of patients; monitor electrolytes incl. Ca, Mg prior to each dose and for at least 8wk after D/C; hold tx for grade 3 or 4 electrolyte abnormalities
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
squamous non-small cell lung CA, untreated metastatic
- [800 mg IV x1 on days 1, 8 of 21-day cycle]
- Info: part of multi-drug chemo regimen
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [see below]
- mild-moderate impairment: no adjustment; severe impairment: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.